Definium Therapeutics, Inc. (DFTX) Stock Ticker
DFTX right now
Market factors today
Unlock the full DFTX picture
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
DFTX stock facts
| Ticker symbol | DFTX |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $4.8B |
| CEO | Robert Barrow |
| Employees | 106 |
| Headquarters | New York, NY, US |
| IPO date | 2016-11-15 |
| Website | definiumtx.com |
What you can see for DFTX on Tickr
Live DFTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the DFTX report.
Rankings
FAQ
What is the ticker symbol for Definium Therapeutics, Inc.?
The ticker symbol for Definium Therapeutics, Inc. is DFTX, listed on the NASDAQ Global Select.
What is DFTX?
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder…